摘要
越来越多的研究表明肥胖与肠道菌群的组成和功能变化密切相关。肠道菌群失调不仅影响肥胖的发病机制,同时也提供了一个新的治疗靶点。胰高血糖素样肽-1(GLP-1)的分泌与肠道菌群具有一定的相关性。近年来,胰高血糖素样肽-1受体激动剂(GLP-1RA)在降低血糖的过程中,由于其突出的减重作用、较少的不良反应,在肥胖病人的减重治疗中备受重视。研究表明,GLP-1RA的减重机制可能与改变肥胖病人肠道菌群结构及代谢产物有关。该文通过总结肠道微生物失调和肥胖之间的关系、GLP-1RA对肥胖病人肠道菌群及其代谢产物的影响以及微生物靶向治疗肥胖的应用前景等3个方面,进一步对未来治疗肥胖的新方法进行展望。
A growing body of research indicates that obesity is closely associated with alterations in the composition and function of the gut microbiota.Dysbiosis of the gut microbiota not only influencess the pathogenesis of obesity but also offers a novel therapeutic target.Secretion of glucagon-like peptide-1(GLP-1)is correlated with the gut microbiota.In recent years,glucagon-like peptide-1 receptor agonists(GLP-1RAs)have garnered significant attention in weight management for patients with obesity due to their pronounced weight-loss effects and favorable safety profile during glycemic control.Studies suggest that the weight-reducing mechanism of GLP-1RAs may involve modulating the gut microbiota structure and metabolic products in obese individuals.This review summarizes three key aspects:the relationship between gut microbial dysbiosis and obesity,the impact of GLP-1RAs on the gut microbiota and its metabolites in obese patients,and the potential application of microbiota-targeted therapies for obesity,thereby providing prospects for future novel obesity treatments.
作者
王蕾
杨坤
薛雪花
WANG Lei;YANG Kun;XUE Xuehua(Endocrine Department,Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Taiyuan,Shanxi 030032,China)
出处
《安徽医药》
2026年第3期451-455,共5页
Anhui Medical and Pharmaceutical Journal
基金
山西省基础研究计划项目(20210302124571)。
